MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jdiacomp.2024.108718

Медицинская библиотека · Journal of diabetes and its complications · 2024

Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial.

Lasschuit Joel Willem Johan, Center Jacqueline Ruth, Greenfield Jerry Richard, Tonks Katherine Thuy Trang, Charcot Foot Quantitative Ultrasound and Denosumab Study (CRUSADES) Investigators

Рандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

AIMS: We aimed to investigate the effect of denosumab on pedal bone health and clinical resolution in active Charcot foot (CN).

METHODS

This multicentre open-label phase 2 randomised controlled trial recruited adults with diabetes mellitus and active CN within 3 months of onset. Participants were randomised to standard care alone, or with denosumab 60 mg subcutaneously. Denosumab was administered at baseline and again at 6 months, unless foot temperature had normalised (i.e. <2 °C compared to contralateral foot). Co-primary outcomes were change in calcaneal Stiffness Index and foot temperature normalisation over 18 months.

RESULTS

Twelve participants per group were analysed; mean age 58 ± 11 years, 83 % male and 92 % had type 2 diabetes. Active CN duration was median 8 (IQR 7-12) weeks. Ninety-two percent were Eichenholtz stage 1 and 96 % involved the midfoot. After 1-month, median decline in Stiffness Index was less in the denosumab verses standard care group (0.5 [IQR -1.0 to 3.9] vs -2.8 [-8.5 to -1.0], p = 0.008). At 18-months, 92 % of the denosumab group attained foot temperature normalisation versus 67 % of the standard care group (p = 0.13).

CONCLUSIONS

Denosumab ameliorated the early decline in calcaneal Stiffness Index associated with active CN. However, no difference in normalisation of foot temperature was observed.

Для цитирования: Lasschuit Joel Willem Johan, Center Jacqueline Ruth, Greenfield Jerry Richard, Tonks Katherine Thuy Trang, Charcot Foot Quantitative Ultrasound and Denosumab Study (CRUSADES) Investigators. Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial.. Journal of diabetes and its complications. 2024. DOI: 10.1016/j.jdiacomp.2024.108718.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.